Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.
about
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell linesAngiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer.NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies.NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivityTumor vascular microenvironment determines responsiveness to photodynamic therapy.Significance of Fractionated Administration of Thalidomide Combined With γ-Ray Irradiation in Terms of Local Tumor Response and Lung Metastasis.Usefulness of Daily Fractionated Administration of Wortmannin Combined With γ-Ray Irradiation in Terms of Local Tumor Response and Lung Metastasis.
P2860
Q33401396-2661C1C2-33A9-4327-B109-4CE31D7CC54EQ33705268-F27626A6-C614-4375-9430-E08F1B036661Q35098017-EEF3448D-8B16-47C4-A220-C13CB168874DQ35165488-F6C9BA73-FF11-4286-9407-5A1B294B3829Q35740663-7D255B15-C1E8-4399-8E7D-CC2D813C5BBBQ35955451-7BEC8C3A-A0AD-43F1-8A9C-4962BA6D71C1Q36507559-6CA45A3A-0712-41A5-BC28-8472BF777AEEQ36544946-66B681E8-A89F-47FE-97DF-73108B46388CQ37092020-9D5DB47D-E215-4925-933C-7E0ADE266A10Q37403232-D311DD30-7D6B-4B16-95A9-83E0D7EDD8DBQ38028791-46F7062D-C214-41FE-9C5A-59BF75722A9AQ39373143-BF4C68A6-5F74-49AF-B1D1-FD94E61ED10FQ39388400-852E31D0-534B-46FC-90AB-6559E13DB572Q45788010-5ABEC744-7E67-4198-B96D-E158B172112BQ47119451-27086207-BF45-4AFF-A76C-5AC656C87B79
P2860
Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.
@ast
Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.
@en
type
label
Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.
@ast
Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.
@en
prefLabel
Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.
@ast
Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.
@en
P2860
P1433
P1476
Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.
@en
P2093
Amit Maity
Eric J Bernhard
P2860
P304
P356
10.1158/0008-5472.CAN-09-3615
P407
P577
2010-02-23T00:00:00Z